Molecular Inflammation Board at the Center for Personalized Medicine
Observational · No treatment assigned · 1 site · University Hospital Tuebingen
Official record & contacts on ClinicalTrials.gov ↗
In plain English
What this trial is testing
Condition(s) listed: Psoriasis (PsO), Psoriasis Arthritis and Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis). This is an observational study: researchers collect information (for example questionnaires, samples, or scans) but the study does not assign a treatment.
Who can join
- Ages 18 and older
- Any sex
Some of the main requirements, copied from the record:
- Chronic inflammatory disorder (PsO, PsA, SpA, IBD)
- Given informed consent
- 18 years of age
There are also 1 reasons someone might not be able to join (exclusion criteria). Only the trial team can confirm whether you qualify.
What's involved
- About 3000 participants are expected to take part.
- Start date: 2022-11-16.
- Main results expected around 2032-11 (estimate from the record).
- 1 study site listed (1 marked recruiting) in Germany.
Main thing being measured
- Therapy persistence (Through study completion, an average of 1 year)
In the researchers’ words
Molecular Inflammation Board at the Center for Personalized Medicine
This is a short automatic summary built from the official record. A fuller plain-English card is coming; until then, please read the official record.
Questions to ask your doctor and the trial team
- Am I likely to qualify, given my health history?
- What would I have to do, and how often would I need to visit?
- Could I get a placebo? What happens to my current treatment?
- What are the possible risks and benefits?
- Are travel or other costs covered?
- What happens after the trial ends?
Official details
| Status | Recruiting |
|---|---|
| Phase | Observational |
| Study type | Observational |
| Conditions | Psoriasis (PsO); Psoriasis Arthritis; Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis); Spondylarthropathies |
| Lead sponsor | University Hospital Tuebingen |
| Collaborators | University Hospital Freiburg; University Hospital Heidelberg; University Hospital Ulm |
| Enrollment | 3000 (estimated) |
| Start date | 2022-11-16 |
| Primary completion (est.) | 2032-11 |
| First posted | 2025-08-20 |
| Last updated | 2025-08-20 |
| Official title | The Molecular Inflammation Board at the Centers for Personalized Medicine at the University Hospitals of Freiburg, Heidelberg, Tübingen and Ulm - A Multicenter Prospective Observational Study |
| ClinicalTrials.gov ID | NCT07132333 |
Interventions
- Biologic Agent (Biological)
Intervention with biologic agents
Full eligibility criteria (from the record)
Inclusion Criteria: * Chronic inflammatory disorder (PsO, PsA, SpA, IBD) * Given informed consent * 18 years of age Exclusion Criteria: * No capacity to consent
Locations (1)
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital of Tübingen - Center for Personalized Medicine | Tübingen | Germany | Recruiting |
For contacts at each site, use the official record.
Information only, not medical advice. Talk to your doctor and the trial team before making any decision about a clinical trial.